• Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*

• Sandoz plans to complete Phase III development program and file for registration in the EU

• Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab

Holzkirchen, 12 February, 2016 – Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF- …

Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region …

• Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achieved

• Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that the proposed biosimilar is highly similar to the reference product.

• Sandoz is the European market leader in both the daily G-CSF class and for biosimilar filgrastim.

Holzkirchen, 11 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, …

Holzkirchen, February 10, 2016 – Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).

In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be: 

• Increasing …

Basel, January 27, 2016 – Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

• Strong growth (cc) in full year sales, core operating income and core EPS[2]
  • Net sales up 5% (cc) and core operating income up 10% (cc)
  • Core operating income margin up 1.3 percentage points (cc)
  • Operating income (-2% cc) down mainly due to amortization of the new oncology assets
  • Net income (-18% cc) impacted by exceptional gains in …